Jeffrey Browne

RESEARCH TRIANGLE PARK, N.C. (June 12, 2002)) - Magellan Pharmaceutical Development, a full-service contract pharmaceutical development organization (PDO) formerly known as Magellan Laboratories and now owned by Cardinal Health, elevates William Stagner, Ph.D., Robert Woodhouse, Ph.D. and Jeffrey Browne, Ph.D., in response to the company's global expansion.
...
In addition, Jeffrey Browne, Ph.D., as executive director of the Pharmaceutics Division where he has served since its inception and manages drug formulation and manufacturing, will take on added leadership responsibilities within the Division.

"Bill, Bob and Jeff have proven their leadership capabilities during their tenures at Magellan, and with these appointments, we have the senior leadership in place to lead Magellan Pharmaceutical Development into the future," says Caudill.